JP7237951B2 - Ｃｄ３８調節抗体 - Google Patents

Ｃｄ３８調節抗体 Download PDF

Info

Publication number
JP7237951B2
JP7237951B2 JP2020518573A JP2020518573A JP7237951B2 JP 7237951 B2 JP7237951 B2 JP 7237951B2 JP 2020518573 A JP2020518573 A JP 2020518573A JP 2020518573 A JP2020518573 A JP 2020518573A JP 7237951 B2 JP7237951 B2 JP 7237951B2
Authority
JP
Japan
Prior art keywords
antibody
seq
sequence
antigen
acd38
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020518573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522281A5 (show.php
JP2020522281A (ja
Inventor
パスカル メルヒールス
アンヌ グビエ
ケヴィン モウルダー
ニナ アイスラー
ジョセフィン サリム
シモーヌ フィロスト
コルソ ベアトリス ゴイエンチェア
ヘマンタ バルーア
ビアンカ プリンツ
Original Assignee
ブラック ベルト セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブラック ベルト セラピューティクス リミテッド filed Critical ブラック ベルト セラピューティクス リミテッド
Publication of JP2020522281A publication Critical patent/JP2020522281A/ja
Publication of JP2020522281A5 publication Critical patent/JP2020522281A5/ja
Application granted granted Critical
Publication of JP7237951B2 publication Critical patent/JP7237951B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020518573A 2017-06-08 2018-06-08 Ｃｄ３８調節抗体 Active JP7237951B2 (ja)

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
US201762517149P 2017-06-08 2017-06-08
US201762517150P 2017-06-08 2017-06-08
US62/517,150 2017-06-08
US62/517,149 2017-06-08
US201762517753P 2017-06-09 2017-06-09
US201762517745P 2017-06-09 2017-06-09
US201762517734P 2017-06-09 2017-06-09
US201762517740P 2017-06-09 2017-06-09
US201762517164P 2017-06-09 2017-06-09
US201762517165P 2017-06-09 2017-06-09
US62/517,164 2017-06-09
US62/517,165 2017-06-09
US62/517,753 2017-06-09
US62/517,745 2017-06-09
US62/517,740 2017-06-09
US62/517,734 2017-06-09
US201762582681P 2017-11-07 2017-11-07
US201762582666P 2017-11-07 2017-11-07
US201762582676P 2017-11-07 2017-11-07
US201762582653P 2017-11-07 2017-11-07
US62/582,653 2017-11-07
US62/582,666 2017-11-07
US62/582,676 2017-11-07
US62/582,681 2017-11-07
PCT/EP2018/065243 WO2018224685A1 (en) 2017-06-08 2018-06-08 Cd38 modulating antibody

Publications (3)

Publication Number Publication Date
JP2020522281A JP2020522281A (ja) 2020-07-30
JP2020522281A5 JP2020522281A5 (show.php) 2021-07-26
JP7237951B2 true JP7237951B2 (ja) 2023-03-13

Family

ID=62620847

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020518573A Active JP7237951B2 (ja) 2017-06-08 2018-06-08 Ｃｄ３８調節抗体
JP2020518572A Active JP7237950B2 (ja) 2017-06-08 2018-06-08 Ｃｄ３８調節抗体
JP2022202855A Active JP7467584B2 (ja) 2017-06-08 2022-12-20 Ｃｄ３８調節抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020518572A Active JP7237950B2 (ja) 2017-06-08 2018-06-08 Ｃｄ３８調節抗体
JP2022202855A Active JP7467584B2 (ja) 2017-06-08 2022-12-20 Ｃｄ３８調節抗体

Country Status (8)

Country Link
US (3) US12343394B2 (show.php)
EP (2) EP3635002A1 (show.php)
JP (3) JP7237951B2 (show.php)
KR (3) KR20250025514A (show.php)
CN (2) CN110997723B (show.php)
AU (3) AU2018280871B2 (show.php)
CA (2) CA3066553A1 (show.php)
WO (2) WO2018224685A1 (show.php)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250025514A (ko) 2017-06-08 2025-02-21 블랙 벨트 테라퓨틱스 리미티드 Cd38 조정 항체
EP3668896A1 (en) 2017-08-16 2020-06-24 Black Belt Therapeutics Limited Cd38 modulating antibody
CN110144008B (zh) * 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
SG11202106963YA (en) 2019-01-11 2021-07-29 Omeros Corp Methods and compositions for treating cancer
WO2020152290A1 (en) * 2019-01-23 2020-07-30 Encefa Cd31 competitors and uses thereof
US12453738B2 (en) 2019-03-12 2025-10-28 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
EP3947463A4 (en) 2019-03-29 2022-12-21 Arcus Biosciences, Inc. TREATMENT OF CANCER USING AN IDENTIFIED ADENOSINE FINGERPRINT
CN114524877A (zh) * 2019-03-29 2022-05-24 索伦托药业有限公司 结合cd38的经工程改造的变异抗体
TW202227493A (zh) 2020-09-10 2022-07-16 美商英創遠達製藥公司 血液篩選之方法
CN114457028A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达cd38抗体的多能干细胞及其衍生物与应用
CN114437215B (zh) * 2020-11-05 2023-02-07 上海麦济生物技术有限公司 抗人cd38抗体及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123950A1 (en) 2005-05-24 2009-05-14 Morphosys Ag Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38
JP2014509187A (ja) 2010-12-30 2014-04-17 武田薬品工業株式会社 結合抗ｃｄ３８抗体
WO2016071355A1 (en) 2014-11-04 2016-05-12 Glenmark Pharmaceuticals S.A. Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) * 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
US20030148321A1 (en) * 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
AU2011202520C1 (en) * 2002-10-17 2016-02-18 Genmab A/S Human monoclonal antibodies against CD20
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
NZ548990A (en) 2004-02-06 2009-06-26 Morphosys Ag Anti-CD38 human antibodies and uses therefor
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
NZ561883A (en) * 2005-03-23 2010-11-26 Genmab As Antibodies against CD38 for treatment of multiple myeloma
EP1872124A4 (en) * 2005-04-19 2008-06-11 Prediction Sciences Llc DIAGNOSIS MARKET FOR BREAST CANCER TREATMENT AND PROGRESSION AND METHOD OF USE THEREOF
KR101512853B1 (ko) 2005-10-12 2015-04-28 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
AU2016228249A1 (en) * 2006-09-26 2016-10-06 Genmab A/S Combination treatment of CD38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
AU2013209322A1 (en) 2006-10-19 2013-08-15 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer
KR101552735B1 (ko) 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
CN101605906A (zh) 2006-12-14 2009-12-16 梅达雷克斯公司 结合cd70的人类抗体及其用途
CA2672468A1 (en) 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
NZ600281A (en) 2006-12-27 2013-03-28 Harvard College Compositions and methods for the treatment of infections and tumors
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
DK2342220T3 (da) 2008-10-06 2021-08-09 Univ British Columbia Metoder og systemer til forudsigelse af misfoldede proteinepitoper
US8642292B2 (en) 2009-09-22 2014-02-04 Probiogen Ag Process for producing molecules containing specialized glycan structures
WO2011035433A1 (en) * 2009-09-23 2011-03-31 University Health Network Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
CN105734678B (zh) 2010-07-16 2019-11-05 阿迪马布有限责任公司 合成多核苷酸文库
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
GB201300346D0 (en) * 2013-01-09 2013-02-20 Biolnvent Internat Ab BiologIcal materials and uses thereof
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
AR095517A1 (es) 2013-03-15 2015-10-21 Genentech Inc ANTICUERPOS CONTRA EL RECEPTOR QUIMIOATRAYENTE EXPRESADO EN CÉLULAS T HELPER 2 (ANTI-CRTh2) Y MÉTODOS DE USO
EP3104882B1 (en) 2014-02-14 2019-06-05 Centrose, Llc Extracellular targeted drug conjugates
EA201691925A1 (ru) 2014-03-28 2017-06-30 Ксенкор, Инк. Биспецифические антитела, которые связываются с cd38 и cd3
MX2017007187A (es) 2014-12-01 2018-01-30 Univ Pennsylvania Construcciones de anticuerpos de adn y metodo para utilizarlas.
US10059774B2 (en) 2015-04-08 2018-08-28 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD38
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
US20160376373A1 (en) 2015-06-24 2016-12-29 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
EP3356415B1 (en) 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
CN115746143A (zh) 2015-10-02 2023-03-07 豪夫迈·罗氏有限公司 对共刺激性tnf受体特异性的双特异性抗体
KR20250025514A (ko) 2017-06-08 2025-02-21 블랙 벨트 테라퓨틱스 리미티드 Cd38 조정 항체
WO2021057978A1 (zh) * 2019-09-27 2021-04-01 南京金斯瑞生物科技有限公司 抗vhh域抗体及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123950A1 (en) 2005-05-24 2009-05-14 Morphosys Ag Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38
JP2014509187A (ja) 2010-12-30 2014-04-17 武田薬品工業株式会社 結合抗ｃｄ３８抗体
WO2016071355A1 (en) 2014-11-04 2016-05-12 Glenmark Pharmaceuticals S.A. Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Blood, 2014, Vol.124, No.21, 3474
Clinical Cancer Research, 2014, Vol.20, No.17, pp.4574-4583

Also Published As

Publication number Publication date
US12161717B2 (en) 2024-12-10
KR20200021068A (ko) 2020-02-27
JP2020522280A (ja) 2020-07-30
NZ760342A (en) 2025-03-28
NZ760448A (en) 2025-03-28
KR102719065B1 (ko) 2024-10-17
US12343394B2 (en) 2025-07-01
AU2018280871B2 (en) 2024-09-26
KR20250025514A (ko) 2025-02-21
CA3066553A1 (en) 2018-12-13
AU2018280869A1 (en) 2020-01-16
CN110997722B (zh) 2023-09-26
AU2018280871A1 (en) 2020-01-16
JP2023030071A (ja) 2023-03-07
JP7237950B2 (ja) 2023-03-13
AU2025201908A1 (en) 2025-04-03
CN110997722A (zh) 2020-04-10
EP3635002A1 (en) 2020-04-15
US20250367286A1 (en) 2025-12-04
AU2018280869B2 (en) 2025-01-02
US20230103584A1 (en) 2023-04-06
AU2018280871A8 (en) 2020-01-30
CN110997723A (zh) 2020-04-10
US20210277138A1 (en) 2021-09-09
JP7467584B2 (ja) 2024-04-15
KR20200021069A (ko) 2020-02-27
CN110997723B (zh) 2023-09-26
WO2018224685A1 (en) 2018-12-13
WO2018224683A1 (en) 2018-12-13
EP3635003A1 (en) 2020-04-15
KR102770106B1 (ko) 2025-02-21
JP2020522281A (ja) 2020-07-30
CA3066555A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
JP7467584B2 (ja) Ｃｄ３８調節抗体
JP7596447B2 (ja) Ｃｄ３８調節抗体
JP7299873B2 (ja) Ｃｄ３８抗体
US12304964B2 (en) CD38 modulating antibody
US11542338B2 (en) CD38 modulating antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210607

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230301

R150 Certificate of patent or registration of utility model

Ref document number: 7237951

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150